Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.

Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, Mullighan CG, Chen L, Bergstraesser E, Bueso-Ramos CE, Emanuel PD, Hasle H, Issa JP, van den Heuvel-Eibrink MM, Locatelli F, Stary J, Trebo M, Wlodarski M, Zecca M, Shannon KM, Niemeyer CM.

Blood. 2009 Aug 27;114(9):1859-63. doi: 10.1182/blood-2009-01-198416. Epub 2009 Jul 1.

2.

Oncogenic Kras initiates leukemia in hematopoietic stem cells.

Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS.

PLoS Biol. 2009 Mar 17;7(3):e59. doi: 10.1371/journal.pbio.1000059.

3.

RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.

Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL, Shih LY.

Leukemia. 2009 Aug;23(8):1426-31. doi: 10.1038/leu.2009.48. Epub 2009 Mar 12.

PMID:
19282830
4.

250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.

Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H, Sekeres MA, Wang XF, McDevitt MA, Maciejewski JP.

Cancer Res. 2008 Dec 15;68(24):10349-57. doi: 10.1158/0008-5472.CAN-08-2754.

5.

Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.

Zhang J, Wang J, Liu Y, Sidik H, Young KH, Lodish HF, Fleming MD.

Blood. 2009 Feb 5;113(6):1304-14. doi: 10.1182/blood-2008-01-134262. Epub 2008 Dec 9.

6.

Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.

Yoshida N, Yagasaki H, Xu Y, Matsuda K, Yoshimi A, Takahashi Y, Hama A, Nishio N, Muramatsu H, Watanabe N, Matsumoto K, Kato K, Ueyama J, Inada H, Goto H, Yabe M, Kudo K, Mimaya J, Kikuchi A, Manabe A, Koike K, Kojima S.

Pediatr Res. 2009 Mar;65(3):334-40. doi: 10.1203/PDR.0b013e3181961d2a.

PMID:
19047918
7.

Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.

Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML.

Cancer Cell. 2008 Oct 7;14(4):335-43. doi: 10.1016/j.ccr.2008.08.014.

8.

Going with the flow: JAK-STAT signaling in JMML.

Kalaitzidis D, Gilliland DG.

Cancer Cell. 2008 Oct 7;14(4):279-80. doi: 10.1016/j.ccr.2008.09.006.

9.

Aberrant GM-CSF signal transduction pathway in juvenile myelomonocytic leukemia assayed by flow cytometric intracellular STAT5 phosphorylation measurement.

Gaipa G, Bugarin C, Longoni D, Cesana S, Molteni C, Faini A, Timeus F, Zecca M, Biondi A.

Leukemia. 2009 Apr;23(4):791-3. doi: 10.1038/leu.2008.265. Epub 2008 Oct 2. No abstract available.

PMID:
18830265
10.

The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation.

Hansen G, Hercus TR, McClure BJ, Stomski FC, Dottore M, Powell J, Ramshaw H, Woodcock JM, Xu Y, Guthridge M, McKinstry WJ, Lopez AF, Parker MW.

Cell. 2008 Aug 8;134(3):496-507. doi: 10.1016/j.cell.2008.05.053.

11.

K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Kindler T, Cornejo MG, Scholl C, Liu J, Leeman DS, Haydu JE, Fröhling S, Lee BH, Gilliland DG.

Blood. 2008 Oct 15;112(8):3373-82. doi: 10.1182/blood-2008-03-147587. Epub 2008 Jul 28.

12.

Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.

Emanuel PD.

Leukemia. 2008 Jul;22(7):1335-42. doi: 10.1038/leu.2008.162. Epub 2008 Jun 12. Review.

PMID:
18548091
13.

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.

Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T.

Nat Genet. 2008 May;40(5):600-8. doi: 10.1038/ng.115. Epub 2008 Mar 30.

14.

FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.

Lee BH, Tothova Z, Levine RL, Anderson K, Buza-Vidas N, Cullen DE, McDowell EP, Adelsperger J, Fröhling S, Huntly BJ, Beran M, Jacobsen SE, Gilliland DG.

Cancer Cell. 2007 Oct;12(4):367-80.

15.

Characterisation of the expression and function of the GM-CSF receptor alpha-chain in mice.

Rosas M, Gordon S, Taylor PR.

Eur J Immunol. 2007 Sep;37(9):2518-28.

16.

K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.

Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS.

Blood. 2007 May 1;109(9):3945-52. Epub 2006 Dec 27.

17.

Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined.

Elliott MA.

Best Pract Res Clin Haematol. 2006;19(3):571-93. Review.

PMID:
16781489
18.

Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.

Parikh C, Subrahmanyam R, Ren R.

Blood. 2006 Oct 1;108(7):2349-57. Epub 2006 Jun 8.

19.

Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia.

Auewarakul CU, Lauhakirti D, Tocharoentanaphol C.

Eur J Haematol. 2006 Jul;77(1):51-6. Epub 2006 Mar 27.

PMID:
16573741
20.

Identification of K-ras as the major regulator for cytokine-dependent Akt activation in erythroid progenitors in vivo.

Zhang J, Lodish HF.

Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14605-10. Epub 2005 Oct 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk